LULU vs MRK: Which Is the Better Buy?
Side-by-side comparison of Lululemon Athletica Inc. and Merck & Co., Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-17.
Lululemon Athletica Inc. · Consumer Cyclical
$116.33
+45.0% upside to fair value
Med Conviction
Grade B-
VS
Merck & Co., Inc. · Healthcare
$113.87
-12.1% upside to fair value
Grade D
High Quality
QuantHub Verdict
LULU has more upside to fair value
(+45.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
LULU |
MRK |
| Current Price |
$116.33 |
$113.87 |
| Fair Value Estimate |
$168.68 |
$100.14 |
| Upside to Fair Value |
+45.0%
|
-12.1%
|
| Market Cap |
$13.2B |
$281.2B |
| Forward P/E |
—
|
32.0x
|
| EV / EBITDA |
5.3x
|
17.3x
|
| Price / Sales |
1.2x
|
4.3x
|
| Price / FCF |
10.3x
|
19.9x
|
| Revenue Growth YoY |
+4.3%
|
+4.3%
|
| Gross Margin |
55.7%
|
75.9%
|
| Operating Margin |
18.2%
|
27.6%
|
| Return on Equity |
31.3%
|
17.9%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
9.69%
|
5.02%
|
| Analyst Consensus |
Hold
|
Hold
|
Investment Thesis
Lululemon Athletica is a premium athletic-apparel retailer whose technical-product innovation, powerful brand, direct-to-consumer retail and e-commerce model, and community-led marketing have historically supported high returns, including a 31.3% ROE, 55.7% gross margin, 18.2% operating margin, and 13.0% net margin. The investment case is now a turnaround rather than a clean compounding story: in…
Merck & Co., Inc. is a leading global healthcare company specializing in pharmaceuticals, vaccines, and animal health products. Its business quality is high, supported by a durable competitive moat anchored in the dominant global position of Keytruda in PD-1/PD-L1 oncology, a strong vaccines portfolio including Gardasil, and scale in R&D and manufacturing. The company benefits from a seasoned lea…
Accumulation Zones
| Metric |
LULU |
MRK |
| Zone Low |
$126.51 |
$75.11 |
| Zone High |
$143.38 |
$85.12 |
| In Buy Zone? |
Yes
|
No
|